The study looked at those who quit within less than three months, and those who discontinued between the three-month mark and one year
Minimum plasma glucose levels in the repaglinide and clopidogrel group before and after starting repaglinide were 145.2 42.9 and 93.3 36.3 mg/dL, respectively
Starting at a lower dose allows your body to adapt to GLP-1 receptor activation, reducing the severity of gastrointestinal side effects
GLP-1 agonists carry a rodent-based thyroid tumor warning, but human data over 7+ years has not confirmed this risk
Clinical trials have tested the effects of GLP-1R agonists in patients with PD, AD, or diabetes-related memory impairment, showing significant improvement in these patients conditions (69)
doi: 10.1016/S0140-6736(18)32261-X 42 GersteinHCColhounHMDagenaisGRDiazRLakshmananMPaisPet al